Vident Investment Advisory’s CASI Pharmaceuticals CASI Stock Holding History

Vident Investment Advisory’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,483	Closed	-$85K	–	1166
2021 Q2	$85K	Hold	5,483	–	–	﹤0.01%	1086
2021 Q1	$132K	Sell	5,483 -3,550	-39%	-$99.7K	﹤0.01%	979
2020 Q4	$266K	Sell	9,033 -37	-0.4%	-$804	0.01%	834
2020 Q3	$139K	Buy	9,070 +2,316	+34%	+$43.6K	0.01%	848
2020 Q2	$169K	Sell	6,754 -1,803	-21%	-$39.2K	0.01%	816
2020 Q1	$175K	Buy	8,557 +1,716	+25%	+$40.9K	0.01%	756
2019 Q4	$211K	Buy	6,841 +1,999	+41%	+$64.8K	0.01%	658
2019 Q3	$162K	Buy	4,842 +2,577	+114%	+$82.7K	0.01%	447
2019 Q2	$72K	Hold	2,265	–	–	0.01%	435
2019 Q1	$65K	Buy	+2,265	New	+$78.9K	﹤0.01%	695

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vident Investment Advisory's CASI Position: Q3 2021 in Review

Vident Investment Advisory sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 5,483 shares — an estimated $85K sold.

Vident Investment Advisory first reported a position in CASI in Q1 2019 and held it in 10 quarters. The position peaked at $266K in Q4 2020. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

Vident Investment Advisory reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Vident Investment Advisory sold 5,483 CASI Pharmaceuticals shares in Q3 2021, an estimated $85K.
Vident Investment Advisory first reported a position in CASI Pharmaceuticals in Q1 2019 and held it in 10 quarters.
Vident Investment Advisory's CASI Pharmaceuticals position peaked at $266K in Q4 2020.
58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.